The new sequencing challenge in HER2+ metastatic breast cancer
One of the most important evolving questions in the management of HER2-positive metastatic breast cancer: the first-line reset and the new sequencing problem. What do we want to achieve?
As outcomes continue to improve with modern HER2-directed therapies, clinicians increasingly face new challenges: treatment goals, optimal sequencing strategies, the duration of disease control, and how best to maximize long-term patient outcomes. The faculty discuss the latest evidence, emerging treatment paradigms and practical considerations for a rapidly changing landscape.
